THE ASSOCIATION BETWEEN MEDICATION ADHERENCE WITH CLINICAL OUTCOME AND QUALITY OF LIFE AMONG PATIENTS WITH MYASTHENIA GRAVIS

Tri Antika Rizki Kusuma Putri, I Made Kariasa, Debby Dahlia

##article.abstract##


Background: Medication adherence remains public health attention which may affect clinical outcomes and quality of life of patients with Myasthenia Gravis (MG). However, studies on medication adherence, and its association with clinical outcome and quality of life been poorly characterized among patients with MG. Objectives: The study aimed to explore the relationship between medication adherence with clinical outcome and quality of life of patients with MG. Methods: A cross-sectional study of patients with myasthenia gravis at 75 patients with MG was conducted at the foundation of MG in Indonesia. Data were collected from May to October 2016. A purposive sampling technique was used to select subject based on inclusion criteria. MG-PRO instrument was used to measure the quality of life and Barthel index to measure functional ability. Also, to evaluate the clinical outcome, Myasthenia Gravis Foundation of America (MGFA) classification was applied. All data were analyzed using a parametric test, namely independent t-test. Results: The results of this study showed a significant association between medication adherence with clinical outcome (p=0.000) and quality of life (p=0.048) among patients with MG. Conclusions: Medication adherence was associated with clinical outcome and quality of life of patients with MG. Nurse and other healthcare professionals need to design an intervention to improve the adherence to medication, not only during hospitalization but also in the rehabilitation phase to prevent from a myasthenia crisis.

 


##article.subject##


adherence, clinical outcome, myasthenia gravis, quality of life

Full Text:

PDF

References


Agborsangaya, C.B., Lau, D., Lahtinen, M., Cooke, T., & Johnson, J. (2012). Health-related quality of life and healthcare utilization in multimorbidity: result of cross-sectional survey. Quality of Life Reasearch, 791-799. Doi:10.1007/s11136-012-0214-7

Alcubierre, N., Martinez-alonso, M., Valls, J., Rubinat, E., Traveset, A., Hernández, M., … Mauricio, D. (2016). Relationship of the adherence to the Mediterranean diet with health-related quality of life and treatment satisfaction in patients with type 2 diabetes mellitus : a post-hoc analysis of a cross-sectional study. Health and Quality of Life Outcomes, 14, 1–7. http://doi.org/10.1186/s12955-016-0473-z

Berrih-aknin, S., & Panse, R. le. (2014). Myasthenia gravis : A comprehensive review of immune dysregulation and etiological mechanisms. Journal of Autoimmunity, 52, 90–100. http://doi.org/10.1016/j.jaut.2013.12.011

Beusterien, K. M., Davis, E. A., Flood, R., Howard, K., & Jordan, J. (2008). HIV patient insight on adhering to medication : a qualitative analysis. AIDS Care, 20(February). http://doi.org/10.1080/09540120701487666

Chen, Y., Chang, Y., Chiu, H., & Yeh, J. (2011). Psychosocial aspects in myasthenic patients treated by plasmapheresis. J Neurol, (258), 1240–1246. http://doi.org/10.1007/s00415-011-5913-4

Conn, V. S., Enriquez, M., Ruppar, T. M., & Chan, K. C. (2016). meta-analyses of theory use in medication adherence intervention research. Am J Health Behav, 40(2), 155–171.

Corwin, elizabeth J. (2008). handbook of pathophysiology (third edit). Philadelphia: Lippincott Williams & Wilkins.

Duncan, D. (2015). Medication adherence in chronic obstructive pulmonary disease. Nurse Prescribing, 172–177.

Gilhus, N. E., & Verschuuren, J. J. (2015). Myasthenia gravis : subgroup classifi cation and therapeutic strategies. The Lancet Neurology, 14(10), 1023–1036. http://doi.org/10.1016/S1474-4422(15)00145-3

Godoy, D. A., Mello, L. J. V. de, Masotti, L., & Napoli, M. Di. (2013). The myasthenic patient in crisis : an update of the management in Neurointensive Care Unit, (April), 627–639. http://doi.org/10.1590/0004-282X20130108

Guo, J., Dang, D., Li, H., & Li, Z. (2014). Current overview of myasthenia gravis and experience in China. Neuroimmunal Neuroinflammation, 1(3), 127–130. http://doi.org/10.4103/2347-8659.143664

Hickey, joanne V. (2014). The clinical Practice of neurological and neurosurgical nursing (seventh ed). Philadelphia: Lippincott Williams & Wilkins.

Jani-Acsadi, A., & Lisak, R. (2007). myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci, 261, 127–133.

Land, kenneth C., & Michalos, A. C. (2012). handbook of social indicators and quality of life research. ( m joseph Sirgy, Ed.). london: springer.

Li, feng bin, Chen, X., Guo, L., & Liu, X. (2012). Evaluation of A Scale of Patient-Reported Outcomes for the Assessment of Myasthenia Gravis Patients in China. Chin J Integr Med, 18(10). http://doi.org/10.1007/s11655-011-0944-3

Meyer, A., & Levy, Y. (2010). Autoimmunity Reviews Chapter 33 : Geoepidemiology of myasthenia gravis. Autoimmunity Reviews, 9(5), A383–A386. http://doi.org/10.1016/j.autrev.2009.11.011

Myasthenia Gravis Association of Western Pennsylvania. (2009). Ocular Myasthenia Gravis.

Ropper, A. H., Samuels, M. A., & Klein, J. P. (2014). Adams and Victor’s Principles of neurology (tenth edit). New york: Mc Graw Hill Education.

Sirgy, m joseph. (2012). the psychology of quality of life hedonic well-being, life satisfication, and eudaimonia (second edi). virginia: springer.

Steb, J. P. (2014). Myasthenia gravis : an update for the clinician. The Journal of Translation Imunology, (175), 408–418. http://doi.org/10.1111/cei.12217

Toyka, K. V., & Gold, R. (2007). Treatment of myasthenia gravis. Scweizer Archiv for Neurologie Und Psychiatrie, 309–321.

Twork, S., Wiesmeth, S., Klewer, J., Pöhlau, D., & Kugler, J. (2010). Quality of life and life circumstances in German myasthenia gravis patients. Health and Quality of Life Outcomes, 8, 1–10.

Woodward, S., & Mestecky, A. (2011). neroscience nursing evidence-based practice. (S. Woodward & A. Mestecky, Eds.). chichester: wiley-blackwell.


Refbacks

  • There are currently no refbacks.


##submission.license.cc.by4.footer##